You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-712-ESGO Real-world prevalence of microsatellite instability testing and related status in patients with recurrent or advanced endometrial cancer initiating first line of therapy in Europe

Alerts

Article menu

Download PDFPDF

Endometrial cancer
2022-RA-712-ESGO Real-world prevalence of microsatellite instability testing and related status in patients with recurrent or advanced endometrial cancer initiating first line of therapy in Europe
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address